C 24 H 19 FeN 3 O 2 S, monoclinic, P21/n (no. 14), a = 8.6762(9) Å,
Source of material
All reagents and solvents were purchased form commercial sources and used as received. The title compound ( Figure) is obtained from a series of reactions from (E)-2-styryl-3H-imidazo [4,5-b] pyridine and ferroceylsulfonyl chloride. 
Atom Site
A solution of (E)-2-styryl-3H-imidazo [4,5-b] pyridine (0.6 g, 2.7 mmol) in acetonitrile (18 mL) was added to amixture of ferrocenylsulfonylchloride (0.72 g, 2.5 mmol) and anhydrous sodium carbonate (0.26 g, 2.5 mmol) with constant stirring. The mixture was heated to re ux for 48 h. The acetonitrile was evaporated under vacuum to leave a brown solid. The crude product was puri ed by column chromatography (SiO 2 , ethyl acetate: petroleum ether v/v = 3:7) to give the title compound (0.49 g, 43% yield) as a dark red crystal, mp: 529-530 K.
Discussion
Imidazo [4,5-b] pyridine and their derivatives possess diverse pharmacological properties, including anticancer, antiviral, and other important biological activities [1] [2] [3] . The asymmetric unit of the title compound contains one complete molecule. There is a imidazo [4,5-b] pyridine ring and a sandwich ferrocenyl moiety. The imidazo [4,5-b] pyridine ring system (C11-C15, N1-N 3 ) is planar, and the dihedral angles between the imidazo [4,5-b] pyridine plane and the substituted cyclopentadienyl plane (C 6 -C 10 ) is 101.49(7)°. There are some di erences in bond lengths and bond angles between the substituted and unsubstituted cyclopentadienyl ring [4, 5] . The bond length of substituted cyclopentadienyl is from 1.424(2)-1.427(2) Å, which in unsubstituted one is from 1.404(3)-1.407(3) Å. There is one intramolecular hydrogen bond between N1 and O1 (d(N1-O1) = 2.889(2) Å), which stabilizes the structure.
